Executive Summary
The sole filing for the S&P 500 Healthcare sector on July 24, 2026, is a routine Schedule 13G/A from Baillie Gifford & Co regarding its passive stake in Moderna, Inc.
The filing reveals a slight increase in absolute share count (from 17.92M to 18.21M shares) but a marginal decrease in ownership percentage (from 4.6% to 4.59%), likely due to share dilution or share repurchases by Moderna. The filing carries neutral sentiment and low materiality (3/10), indicating no change in control intent or activist pressure. With only one filing and no period-over-period financial comparisons, insider transactions, forward-looking guidance, or capital allocation data available, the digest is necessarily limited in breadth. However, the passive nature of this filing and the stable, large stake suggest continued institutional confidence in Moderna's long-term prospects, even as the broader healthcare sector faces headwinds from regulatory and pricing pressures.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Schedule 13G
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from July 23, 2026.
Investment Signals (6)
- Moderna (Baillie Gifford) (BULLISH)▲
Baillie Gifford increased its absolute share count by 1.6% (from 17.92M to 18.21M shares) while its ownership percentage dipped slightly from 4.6% to 4.59%, likely due to Moderna's share repurchase activity or dilution from equity compensation. This signals continued institutional conviction despite a modest relative stake decline
- Moderna (Passive Intent) (BULLISH)▲
The filing under Rule 13d-1(b) certifies passive investment intent, meaning Baillie Gifford has no plans to influence control. This removes overhang risk of activist disruption and supports a stable shareholder base
- Moderna (Stake Stability) (BULLISH)▲
The 4.59% stake remains substantial and nearly unchanged from the prior period, indicating no panic selling or strategic reduction by a top-10 institutional holder. This is a vote of confidence in Moderna's post-COVID pipeline strategy
- Moderna (No Insider Activity) (NEUTRAL)▲
The absence of any insider transactions (buys or sells) in the filing period suggests management is not signaling conviction or concern through personal trades. Neutral signal, but no red flags
- Moderna (No Guidance Change) (NEUTRAL)▲
With no forward-looking statements or guidance updates in this filing, the market lacks new directional cues. The stock will continue to trade on pipeline catalysts (RSV, flu, cancer vaccines) rather than ownership structure
- Moderna (Capital Allocation Silence) (NEUTRAL)▲
No dividend, buyback, or capital allocation data was disclosed in this filing. Investors should monitor Moderna's upcoming earnings for updates on its $3B+ buyback program and R&D spending plans
Risk Flags (3)
- Moderna/Stake Dilution Risk↓ [MEDIUM RISK]▼
Baillie Gifford's ownership percentage declined from 4.6% to 4.59% despite adding shares, implying Moderna's total share count increased. If dilution continues, it could pressure EPS and signal aggressive equity compensation or secondary offerings
- Moderna/Concentration Risk↓ [LOW RISK]▼
With Baillie Gifford holding 4.59% and other top institutions likely holding similar stakes, Moderna's shareholder base is concentrated. Any sudden liquidation by a large holder could cause significant price dislocation
-
The 13G/A filing provides no operational or financial updates. Investors relying solely on this filing miss critical data on revenue trends, margin compression, or
Filing Analyses
(1)
24-07-2026
Baillie Gifford & Co filed a Schedule 13G/A with the SEC on July 24, 2026, disclosing beneficial ownership of 18,206,778 shares of Moderna, Inc. common stock as of June 30, 2026, representing a 4.59% stake. The filing indicates a slight decrease in ownership from the prior period, with the number of shares held dropping from 17,920,410 to 18,206,778 (though the total increased, the percentage decreased from 4.6% to 4.59%). The filing is a routine update under Rule 13d-1(b) and does not signal any change in control intent.
- · Baillie Gifford & Co is an investment adviser based in Edinburgh, Scotland.
- · The filing is made under Rule 13d-1(b), indicating passive investment intent.
- · The filer certifies that securities were acquired in the ordinary course of business and not to influence control.
- · No sole dispositive power is reported (0 shares), while shared dispositive power is 18,206,778 shares.
Get daily alerts with 6 investment signals, 3 risk alerts and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →July 27, 2026
US Pre-Market SEC Filings Roundup — July 27, 2026
US Pre-Market SEC Filings Roundup
July 27, 2026
US Merger & Acquisition SEC Filings — July 27, 2026
US Merger & Acquisition SEC Filings
July 27, 2026
USA Insider Trading Pulse — July 27, 2026
USA Insider Trading Pulse
July 27, 2026
US Executive Officer Management Changes SEC — July 27, 2026
US Executive Officer Management Changes SEC